Jump to content

Probiotic

From Wikipedia, the free encyclopedia

Not to be confused with Prebiotics, food compounds that induce the growth or activity of microorganisms.
A bottle of Yakult, a probiotic drink containing Lactobacillus paracasei

Probiotics are live microorganisms promoted with claims that they provide health benefits when consumed, generally by improving or restoring the gut microbiota.[1][2] Probiotics are considered generally safe to consume, but may cause bacteria-host interactions and unwanted side effects in rare cases.[3][4][5] There is some evidence that probiotics are beneficial for some conditions, such as helping to ease some symptoms of irritable bowel syndrome (IBS). However, many claimed health benefits, such as treating eczema, lack substantial scientific support.[1]

The first discovered probiotic was a certain strain of bacillus in Bulgarian yoghurt, called Lactobacillus bulgaricus. The discovery was made in 1905 by Bulgarian physician and microbiologist Stamen Grigorov. The modern-day theory is generally attributed to Russian Nobel laureate Élie Metchnikoff, who postulated around 1907 that yoghurt-consuming Bulgarian peasants lived longer.[6]

A growing probiotics market has led to the need for stricter requirements for scientific substantiation of putative benefits conferred by microorganisms claimed to be probiotic.[7] Although some evidence claimed benefits are marketed towards using probiotic, such as reducing gastrointestinal discomfort, improving immune health,[8] relieving constipation, or avoiding the common cold, such claims are strain-specific and cannot be extrapolated to other strains.[7][9][10] As of 2019, numerous applications for approval of health claims by European manufacturers of probiotic dietary supplements have been rejected by the European Food Safety Authority for insufficient evidence of beneficial mechanism or efficacy.[8][11]

Definition

[edit]

An October 2001 report by the World Health Organization (WHO) defines probiotics as "live microorganisms which when administered in adequate amounts confer a health benefit on the host."[12][13] Following this definition, a working group convened by the Food and Agriculture Organization (FAO)/WHO in May 2002 issued the Guidelines for the Evaluation of Probiotics in Food.[14] A consensus definition of the term probiotics, based on available information and scientific evidence, was adopted after the aforementioned joint expert consultation between the FAO of the United Nations and the WHO. This effort was accompanied by local governmental and supra-governmental regulatory bodies' requirements to better characterize health claims substantiations.[citation needed]

That first global effort was further developed in 2010; two expert groups of academic scientists and industry representatives made recommendations for the evaluation and validation of probiotic health claims.[15][16] The same principles emerged from those two groups as were expressed in the "Guidelines" of FAO/WHO in 2002. This definition, though widely adopted, is not acceptable to the European Food Safety Authority because it embeds a health claim that is not measurable.[7]

A group of scientific experts assembled in Canada in October 2013 to discuss the scope and appropriate use of the term "probiotic", adjusting the definition to be "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host."[17]

In food

[edit]

Live probiotic cultures are part of fermented dairy products, other fermented foods, and probiotic-fortified foods.[18]

Lactic acid bacteria (LABs), which are food fermenting bacteria, have the ability to prevent food spoilage and can improve the nutritive value of the foods they inhabit. Acid fermentation (as well as salting), remains one of the most practical methods of preservation of fresh vegetables, cereal gruels, and milk-cereal mixtures due to its low cost and energy requirements.[19]

Fermented products that contain lactic acid bacteria include vegetables such as pickled vegetables,[20] kimchi,[20][21] pao cai,[22] and sauerkraut;[23] sourdough bread or bread-like products made without wheat or rye flour, amino acid/peptide meat-flavored sauces and pastes produced by fermentation of cereals and legumes; fermented cereal-fish-shrimp mixtures and fermented meats;[19] soy products such as tempeh,[24] miso,[25] and soy sauce;[26] dairy products such as yogurt, kefir,[27] buttermilk;[28] and non-dairy products such as bee pollen.[29]

More precisely, sauerkraut contains the bacteria Leuconostoc mesenteroides, Lactobacillus plantarum, Pediococcus pentosaceus, Lactobacillus brevis, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, Lactobacillus coryniformis, and Weissella spp.[30] Kimchi contains the bacteria Leuconostoc spp., Weissella spp., and Lactobacillus spp. Pao cai contains L. pentosus, L. plantarum , Leuconostoc mesenteroides , L. brevis, L. lactis, and L. fermentum. A list of many other bacteria found in several Asian fermented fruits and vegetables also is available.[31][32] Kefir contains Lactobacillus acidophilus, Bifidobacterium bifidum, Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus helveticus, Lactobacillus kefiranofaciens, Lactococcus lactis, and Leuconostoc species.[33][34] Buttermilk contains either Lactococcus lactis or L. bulgaricus. Other acidic bacteria, said to be probiotic,[35][36] can be found in kombucha, including Gluconacetobacter xylinus,[37][38] Zygosaccharomyces sp., Acetobacter pasteurianus, Acetobacter aceti, and Gluconobacter oxydans.[39]

Side effects

[edit]

The manipulation of the gut microbiota is complex and may cause bacteria-host interactions.[5] Though probiotics are considered safe, some have concerns about their safety in certain cases.[5][40] Some people, such as those with immunodeficiency, short bowel syndrome, central venous catheters, and cardiac valve disease, and premature infants, may be at higher risk for adverse events.[3] In severely ill people with inflammatory bowel disease, a risk exists for the passage of viable bacteria from the gastrointestinal tract to the internal organs (bacterial translocation) as a consequence of bacteremia, which can cause adverse health consequences.[5] Rarely, consumption of probiotics by children with lowered immune system function or who are already critically ill may result in bacteremia or fungemia (i.e., bacteria or fungi in the blood), which can lead to sepsis, a potentially fatal disease.[4]

Probiotic supplements typically contain between one and ten billion colony-forming units (CFUs) per dose.[41] A higher number of CFUs does not provide additional probiotic effects, but may have unintended consequences of causing digestive discomfort, such as bloating, gas, and diarrhea.[41][42]

Lactobacillus species have been suggested to contribute to obesity in humans, but no evidence of this relationship has been found.[43]

Consumption

[edit]

In 2015, the global retail market value for probiotics was US$41 billion, including sales of probiotic supplements, fermented milk products, and yogurt, which alone accounted for 75% of total consumption.[44] Innovation in probiotic products in 2015 was mainly from supplements, which produced US$4 billion and was projected to grow 37% globally by 2020.[44] Consumption of yogurt products in China has increased by 20% per year since 2014.[45]

Regulation

[edit]

As of 2019, the European Food Safety Authority has rejected all petitions by commercial manufacturers for health claims on probiotic products in Europe due to insufficient evidence for a cause-and-effect mechanism for benefit, thus inconclusive proof of effectiveness.[7][8][11] The European Commission placed a ban on putting the word "probiotic" on the packaging of products because such labeling misleads consumers to believe a health benefit is provided by the product when no scientific proof exists to demonstrate that health effect.[7][46][47][48]

In the United States, the Food and Drug Administration (FDA) and Federal Trade Commission (FTC) have issued warning letters and imposed punishment on various manufacturers of probiotic products whose labels claim to treat a disease or condition.[10][49][50] Food product labeling requires language approved by the FDA, so probiotic manufacturers have received warning letters for making disease or treatment claims.[10][50] The FTC has taken punitive actions, including a US$21 million fine coordinated by 39 different state governments against a major probiotic manufacturer for deceptive advertising and exaggerated claims of health benefits for yogurt and probiotic dairy drink.[49]

In Vietnam, the Vietnam Food Administration (VFA) under the Ministry of Health, in collaboration with other relevant authorities, oversees and addresses violations related to probiotic products. This includes issuing warnings, imposing administrative penalties,[51] demanding product recalls[52][53] and coordinating with other agencies.[54][55]

Yogurt labeling

[edit]

The National Yogurt Association (NYA) of the United States gives a "Live & Active Cultures Seal" to refrigerated yogurt products that contain 100 million cells per gram, or frozen yogurt products that contain 10 million cells per gram at the time of manufacture.[56] In 2002, the FDA and WHO recommended that "the minimum viable numbers of each probiotic strain at the end of the shelf-life" be reported on labeling,[57] but most companies that give a number report the viable cell count at the date of manufacture, a number that could be much higher than that which exists at consumption.[58] Because of the variability in storage conditions and time before eating, exactly how many active culture cells remain at the time of consumption is difficult to determine. The survival of probiotics was strongly dependent on the storage temperature and remarkable viability loss occurred in room temperature compared to refrigerated storage.[59]

History

[edit]

Probiotics have received renewed attention in the 21st century from product manufacturers, research studies, and consumers. Their history can be traced to the first use of cheese and fermented products, which were well-known to the Greeks and Romans who recommended their consumption.[60] The fermentation of dairy foods represents one of the oldest techniques for food preservation.[61]

Élie Metchnikoff first suggested the possibility of colonizing the gut with beneficial bacteria in the early 20th century.

The original modern hypothesis of the positive role played by certain bacteria was first introduced by Russian scientist and Nobel laureate Élie Metchnikoff, who in 1907 suggested that it would be possible to modify the gut microbiota and to replace harmful microbes with useful microbes.[62] Metchnikoff, at that time a professor at the Pasteur Institute in Paris, proposed the hypothesis that the aging process results from the activity of putrefactive (proteolytic) microbes producing toxic substances in the large bowel. Proteolytic bacteria such as clostridia, which are part of the normal gut microbiota, produce toxic substances including phenols, indols, and ammonia from the digestion of proteins. According to Metchnikoff, these compounds were responsible for what he called "intestinal autointoxication", which would cause the physical changes associated with old age.[63]

At that time, milk fermented with lactobacillales were known to inhibit the growth of proteolytic bacteria because of the low pH produced by the fermentation of lactose. Metchnikoff had also observed that certain rural populations in Europe, for example in Bulgaria and the Russian steppes, who lived largely on milk fermented by lactic-acid bacteria, were exceptionally long-lived. Based on these observations, Metchnikoff proposed that consumption of fermented milk would "seed" the intestine with harmless lactic-acid bacteria and decrease the intestinal pH, and that this would suppress the growth of proteolytic bacteria. Metchnikoff himself introduced in his diet sour milk fermented with the bacteria he called "Bulgarian Bacillus" and believed his health benefited. Friends in Paris soon followed his example and physicians began prescribing the sour-milk diet for their patients.[64]

Bifidobacteria was first isolated from a breastfed infant by Henry Tissier, who also worked at the Pasteur Institute. The isolated bacterium named Bacillus bifidus communis[65] was later renamed to the genus Bifidobacterium.[66] Tissier found that bifidobacteria are dominant in the gut microbiota of breast-fed babies and he observed clinical benefits from treating infant diarrhea with bifidobacteria.

During an outbreak of shigellosis in 1917, German professor Alfred Nissle isolated a strain of Escherichia coli from the feces of a soldier who was not affected by the disease.[67] Methods of treating infectious diseases were needed at that time when antibiotics were not yet available, and Nissle used the E. coli Nissle 1917 strain in acute gastrointestinal infectious salmonellosis and shigellosis.[68]

In 1920, Rettger and Cheplin reported that Metchnikoff's "Bulgarian Bacillus", later called Lactobacillus delbrueckii subsp. bulgaricus, could not live in the human intestine.[69][non-primary source needed] They conducted experiments involving rats and humans volunteers, feeding them with Lactobacillus acidophilus. They observed the disappearance of the pathogenic protist Balantidium coli as well as of other gas-producing bacteria.[69] Rettger further explored the possibilities of L. acidophilus, and reasoned that bacteria originating from the gut were more likely to produce the desired effect in this environment. In 1935, certain strains of L. acidophilus were found very active when implanted in the human digestive tract.[70][non-primary source needed]

Contrasting antibiotics, probiotics were defined as microbially derived factors that stimulate the growth of other microorganisms. In 1989, Roy Fuller suggested a definition of probiotics that have been widely used: "A live microbial feed supplement which beneficially affects the host animal by improving its intestinal microbial balance."[71] Fuller's definition emphasizes the requirement of viability for probiotics and introduces the aspect of a beneficial effect on the host.

The term "probiotic" originally referred to microorganisms that have effects on other microorganisms.[72] The concept of probiotics involved the notion that substances secreted by one microorganism stimulated the growth of another microorganism. The term was used again[73] to describe tissue extracts that stimulated microbial growth. The term probiotics was taken up by Parker,[74] who defined the concept as, "Organisms and substances that have a beneficial effect on the host animal by contributing to its intestinal microbial balance." Later, the definition was greatly improved by Fuller,[71] whose explanation was very close to the definition used today. Fuller described probiotics as a "live microbial feed supplement which beneficially affects the host animal by improving its intestinal microbial balance." He stressed two important claims for probiotics: the viable nature of probiotics and the capacity to help with intestinal balance.

In the following decades, intestinal lactic-acid bacterial species with alleged health-beneficial properties were introduced as probiotics, including Lactobacillus rhamnosus, Lactobacillus casei, and Lactobacillus johnsonii.[75]

Etymology

[edit]

Some literature gives the word a full Greek etymology,[76][77] but it appears to be a composite of the Latin preposition pro, meaning 'for', and the Greek adjective βιωτικός (biōtikos), meaning 'fit for life, lively',[78] the latter deriving from the noun βίος (bios), meaning 'life'.[79] The term contrasts etymologically with the term antibiotic, although it is not a complete antonym. The related term prebiotic comes from the Latin prae, meaning 'before', and refers to a substance that is not digested, but rather may be fermented to promote the growth of beneficial intestinal microorganisms.[80]

Research

[edit]

As food products or dietary supplements, probiotics are under preliminary research to evaluate if they provide any effect on health.[2][7][81] In all cases proposed as health claims to the European Food Safety Authority, the scientific evidence remains insufficient to prove a cause-and-effect relationship between consumption of probiotic products and any health benefit.[7][82] There is no scientific basis for extrapolating an effect from a tested strain to an untested strain.[2][83][84] Improved health through gut flora modulation appears to be directly related to long-term dietary changes.[7][85] Claims that some lactobacilli may contribute to weight gain in some humans[86][87] remain controversial.[88]

Acute otitis media

[edit]

There is inconsistency in the results of different groups of 3488 children as reported in a Cochrane review.[89] Also, it shows no significant difference regarding the adverse effects between probiotic and the other comparators.[89]

Allergies

[edit]

Only limited, low-quality evidence exists to indicate that probiotics are helpful for treating people with milk allergy.[90] A 2015 review showed low-quality evidence that probiotics given directly to infants with eczema, or in infants whose mothers used probiotics during the last trimester of pregnancy and breastfeeding, had lower risk of eczema.[91]

Asthma

[edit]

It is unclear whether probiotic supplementation helps with childhood asthma, as the quality of research evidence is low.[92]

Antibiotic-associated diarrhea

[edit]

Antibiotics are a common treatment for children, with 11% to 40% of antibiotic-treated children developing diarrhea.[93] Antibiotic-associated diarrhea (AAD) results from an imbalance in the colonic microbiota caused by antibiotic therapy.[93] These microbial community alterations result in changes in carbohydrate metabolism, with decreased short-chain fatty acid absorption and osmotic diarrhea as a result. A 2015 Cochrane review concluded that a protective effect of some probiotics existed for AAD in children.[93] The known risks of using probiotics for treating Clostridioides difficile outweighs the uncertain benefits.[94]

Probiotic treatment might reduce the incidence and severity of AAD as indicated in several meta-analyses.[95][96][97] For example, treatment with probiotic formulations including L. rhamnosus may reduce the risk of AAD, improve stool consistency during antibiotic therapy, and enhance the immune response after vaccination.[98]

The potential efficacy of probiotics to treat AAD depends on the probiotic strains and dosage.[99][100] One review recommended for children L. rhamnosus or Saccharomyces boulardii at 5 to 40 billion colony-forming units/day, given the modest number needed to treat and the likelihood that adverse events are very rare.[93] The same review stated that probiotic use should be avoided in pediatric populations at risk for adverse events, such as severely debilitated or immune-compromised children.[citation needed]

Bacterial vaginosis

[edit]

Probiotic treatment of bacterial vaginosis is the application or ingestion of bacterial species found in the healthy vagina to cure the infection of bacteria causing bacterial vaginosis. This treatment is based on the observation that 70% of healthy females have a group of bacteria in the genus Lactobacillus that dominate the population of organisms in the vagina. Specific strains of lactobacilli inhibit the growth of bacteria causing BV by producing H2O2, lactic acid, and/or bacteriocins, and/or inhibit the adherence of Gardnerella vaginalis to the vaginal epithelium, which prevents the infection from occurring in the vagina.[101] Currently, the success of probiotic treatment has been mixed, since the use of probiotics to restore healthy populations of Lactobacillus has not been standardized. Often, standard antibiotic treatment is used at the same time that probiotics are being tested. In addition, some groups of women respond to treatment based upon ethnicity, age, number of sexual partners, pregnancy, and the pathogens causing bacterial vaginosis.[102] In 2013, researchers found that administration of hydrogen peroxide-producing strains, such as L. acidophilus and L. rhamnosus, were able to normalize vaginal pH and rebalance the vaginal microbiota, preventing and alleviating bacterial vaginosis.[103]

Blood pressure

[edit]

As of 2017, only limited evidence indicated any direct link between high blood pressure and gut microbiota.[104]

Cholesterol

[edit]

A 2002 meta-analysis that included five double-blind trials examining the short-term (2–8 weeks) effects of a yogurt with probiotic strains on serum cholesterol levels found little effect of 8.5 mg/dL (0.22 mmol/L) (4% decrease) in total cholesterol concentration, and a decrease of 7.7 mg/dL (0.2 mmol/L) (5% decrease) in serum LDL concentration.[105]

Depression and anxiety

[edit]

A 2019 meta-analysis found low-quality evidence for probiotics having a small improvement in depression and anxiety.[106] A 2020 review found probiotics might improve depression, but more studies are needed.[107]

Diarrhea

[edit]

Some probiotics are suggested as a possible treatment for various forms of gastroenteritis.[108] As a treatment for infectious diarrhea, probiotics are of no benefit to people who have the condition for more than two days, and there is no evidence they lessen the duration of diarrhea overall.[109]

Dermatitis

[edit]

Probiotics are commonly given to breastfeeding mothers and their young children to prevent eczema (dermatitis), but no good evidence shows efficacy for this purpose.[110] There is little evidence to support the use of probiotics to treat atopic dermatitis, and some risk of adverse effects.[111] The American Academy of Dermatology stated: "The use of probiotics/prebiotics for the treatment of patients with established atopic dermatitis is not recommended due to inconsistent evidence".[112]

Glycemic control

[edit]

According to an umbrella review of meta-analyses of randomized controlled trials, probiotics supplementation reduces glucose homeostasis. This can be an effective therapy for lowering high blood sugar levels unless the body becomes hypoglycemic; caution and glucose monitoring are necessary to avoid this. [113]

Helicobacter pylori

[edit]

Some strains of lactic acid bacteria (LAB) may affect Helicobacter pylori infections (which may cause peptic ulcers) in adults when used in combination with standard medical treatments, but no standard in medical practice or regulatory approval exists for such treatment.[114] The only peer-reviewed treatments for H. pylori to date all include various Antibiotic Regimens.[115]

Immune function and infections

[edit]

Some strains of LAB may affect pathogens by means of competitive inhibition (i.e., by competing for growth) and some evidence suggests they may improve immune function by increasing the number of IgA-producing plasma cells and increasing or improving phagocytosis, as well as increasing the proportion of T lymphocytes and natural killer cells.[116][117] LAB products might aid in the treatment of acute diarrhea and possibly affect rotavirus infections in children and travelers' diarrhea in adults,[116][117] but no products are approved for such indications. There are weak evidence probiotics might lower the incidence of acute upper respiratory tract infections in adults, they were better than placebo or no treatment.[118]

Probiotics do not appear to change the risk of infection in older people.[119]

Inflammatory bowel disease

[edit]

The use of oral probiotic supplements to modify the composition and behavior of the microbiome has been considered as a possible therapy for both induction and maintenance of remission in people with Crohn's disease and ulcerative colitis. A Cochrane review in 2020 did not find clear evidence of improved remission likelihood, nor lower adverse events, in people with Crohn's disease, following probiotic treatment. [120]

For ulcerative colitis, there is low-certainty evidence that probiotic supplements may increase the probability of clinical remission. [121] People receiving probiotics were 73% more likely to experience disease remission and over 2x as likely to report improvement in symptoms compared to those receiving a placebo, with no clear difference in minor or serious adverse effects. [121]Although there was no clear evidence of greater remission when probiotic supplements were compared with 5‐aminosalicylic acid treatment as a monotherapy, the likelihood of remission was 22% higher if probiotics were used in combination with 5-aminosalicylic acid therapy. [121] Whereas in people who are already in remission, it is unclear whether probiotics help to prevent future relapse, either as a monotherapy or combination therapy. [122]

Irritable bowel syndrome

[edit]

Probiotics are under study for their potential to affect irritable bowel syndrome, although uncertainty remains around which type of probiotic works best, and around the size of possible effect.[123][124]

Necrotizing enterocolitis

[edit]

Several clinical studies provide evidence for the potential of probiotics to lower the risk of necrotizing enterocolitis and mortality in premature infants. One meta-analysis indicated that probiotics reduce these risks by more than 50% compared with controls but that further, large, high-quality trials were needed to inform policy and practice.[125]

Pregnancy

[edit]

A Cochrane systematic review found no good evidence that probiotics were of benefit in reducing the risk of gestational diabetes, but good evidence that they increased the risk of pre-eclampsia. For this reason, the use of probiotics in pregnancy was advised against.[126]

Recurrent abdominal pain

[edit]

A 2017 review based on moderate to low-quality evidence suggests that probiotics may be helpful in relieving pain in the short term in children with recurrent abdominal pain, but the proper strain and dosage are not known.[127]

Dry eye

[edit]

A clinical study investigating the impact of probiotics in relieving the signs and symptoms of dry eye revealed promising results for the ophthalmic formulation of Latilactobacillus sakei, while the oral probiotic demonstrated no discernible benefits.[128]

Urinary tract

[edit]

There is limited evidence indicating probiotics are of benefit in the management of infection or inflammation of the urinary tract.[129] One literature review found Lactobacillus probiotic supplements appeared to increase vaginal lactobacilli levels, thus reducing the incidence of vaginal infections in otherwise healthy adult women.[130]

General research

[edit]

Formulations

[edit]

Supplements such as tablets, capsules, powders, and sachets containing bacteria have been studied. However, probiotics taken orally can be destroyed by the acidic conditions of the stomach. As of 2010, a number of microencapsulation techniques were being developed to address this problem.[131]

Multiple probiotics

[edit]

Preliminary research is evaluating the potential physiological effects of multiple probiotic strains, as opposed to a single strain.[132][133] As the human gut may contain tens of thousands of microbial species, one theory indicates that this diverse environment may benefit from consuming multiple probiotic strains, an effect that remains scientifically unconfirmed.[citation needed]

Strains

[edit]

Only preliminary evidence exists for most probiotic health claims. Even for the most studied probiotic strains, few have been sufficiently developed in basic and clinical research to warrant approval for health claim status by a regulatory agency such as the FDA or EFSA, and as of 2010, no claims had been approved by those two agencies.[7] Some experts are skeptical about the efficacy of different probiotic strains and believe that not all subjects benefit from probiotics.[7][134]

Storage temperature

[edit]

Multiple studies have shown that there is a significant difference in the survival rate of Lactobacillus and Bifidobacterium under refrigerated (4°C) and room temperature (25°C) storage conditions. At room temperature (25±1°C), the number of  probiotics decreased by 5 to 6 logarithmic units (down to 1/100,000) after 90 days of storage. In contrast, no significant change in the number of probiotics was observed under refrigerated conditions (4 ± 1°C).[135]

Scientific guidelines for testing

[edit]

First, probiotics must be alive when administered.[71][136][137] One of the concerns throughout the scientific literature resides in the viability and reproducibility on a large scale of observed results for specific studies, as well as the viability and stability during use and storage, and finally the ability to survive in stomach acids and then in the intestinal ecosystem.[7][failed verification]

Second, probiotics must have undergone controlled evaluation to document health benefits in the target host. Only products that contain live organisms shown in reproducible human studies to confer a health benefit may claim to be probiotic.[7][138][139] The correct definition of health benefit, backed with solid scientific evidence, is a strong element for the proper identification and assessment of the effect of a probiotic. This aspect is a challenge for scientific and industrial investigations because several difficulties arise, such as variability in the site for probiotic use (oral, vaginal, intestinal) and mode of application.[71]

Third, the probiotic candidate must be a taxonomically defined microbe or combination of microbes (genus, species, and strain level). It is commonly admitted that most effects of probiotics are strain-specific and cannot be extended to other probiotics of the same genus or species.[136] This calls for precise identification of the strain, i.e. genotypic and phenotypic characterization of the tested microorganism.[15]

Fourth, probiotics must be safe for their intended use. The 2002 FAO/WHO guidelines recommend that, though bacteria may be generally recognized as safe (GRAS), the safety of the potential probiotic be assessed by the minimum required tests: [140]

  • Assessment of certain metabolic activities (e.g. D-lactate production, bile salt deconjugation)
  • Assessment of side effects in human studies
  • Determination of antibiotic resistance patterns
  • Epidemiological surveillance of adverse incidents in consumers (aftermarket)
  • If the strain under evaluation belongs to a species known to produce toxins in mammals, it must be tested for toxin production. One possible scheme for testing toxin production has been recommended by the EU Scientific Committee on Animal Nutrition.[141]
  • If the strain under evaluation belongs to a species with known hemolytic potential, determination of hemolytic activity is required.

In Europe, EFSA adopted a premarket system for the safety assessment of microbial species used in food and feed productions to set priorities for the need for risk assessment. The assessment is made for certain microorganisms; if the result is favorable, it leads to "Qualified Presumption of Safety" status.[142]

See also

[edit]

References

[edit]
  1. ^ a b "Probiotics". National Health Service. November 27, 2018. Archived from the original on April 20, 2021. Retrieved November 2, 2019.
  2. ^ a b c "Probiotics: What You Need To Know". National Center for Complementary and Integrative Health, US National Institutes of Health. August 1, 2019. Archived from the original on September 17, 2018. Retrieved November 10, 2019.
  3. ^ a b Doron S, Snydman DR (2015). "Risk and safety of probiotics". Clin Infect Dis (Review). 60 (Suppl 2): S129–234. doi:10.1093/cid/civ085. PMC 4490230. PMID 25922398.
  4. ^ a b Singhi SC, Kumar S (2016). "Probiotics in critically ill children". F1000Res (Review). 5: 407. doi:10.12688/f1000research.7630.1. PMC 4813632. PMID 27081478.
  5. ^ a b c d Durchschein F, Petritsch W, Hammer HF (2016). "Diet therapy for inflammatory bowel diseases: The established and the new". World J Gastroenterol (Review). 22 (7): 2179–2194. doi:10.3748/wjg.v22.i7.2179. PMC 4734995. PMID 26900283.
  6. ^ Brown AC, Valiere A (January 1, 2004). "Probiotics and Medical Nutrition Therapy". Nutrition in Clinical Care. 7 (2): 56–68. ISSN 1096-6781. PMC 1482314. PMID 15481739.
  7. ^ a b c d e f g h i j k l Rijkers GT, de Vos WM, Brummer RJ, et al. (2011). "Health benefits and health claims of probiotics: Bridging science and marketing". British Journal of Nutrition. 106 (9): 1291–1296. doi:10.1017/S000711451100287X. PMID 21861940.
  8. ^ a b c Turck D, Castenmiller J, De Henauw S, et al. (April 15, 2019). "Nutrimune and immune defence against pathogens in the gastrointestinal and upper respiratory tracts: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006". EFSA Journal. 17 (4). European Food Safety Authority, Panel on Nutrition, Novel Foods and Food Allergens: e05656. doi:10.2903/j.efsa.2019.5656. PMC 7009160. PMID 32626282.
  9. ^ Slashinski MJ, McCurdy SA, Achenbaum LS, et al. (2012). "'Snake-oil,' 'quack medicine,' and 'industrially cultured organisms:' biovalue and the commercialization of human microbiome research". BMC Medical Ethics. 13: 28. doi:10.1186/1472-6939-13-28. PMC 3512494. PMID 23110633.
  10. ^ a b c Engle MK, Roosevelt MW, Waltrip EA (November 22, 2011). "Warning letter to CocoKefir LLC". Compliance Branch, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration and Federal Trade Commission. Archived from the original on October 23, 2016. Retrieved June 4, 2016.{{cite web}}: CS1 maint: bot: original URL status unknown (link)
  11. ^ a b Chu W (April 18, 2019). "Heinz reels from latest probiotic health claim rejection by EFSA". NutraIngredients.com, William Reed Business Media Ltd. Archived from the original on October 20, 2020. Retrieved May 11, 2019.
  12. ^ Schlundt J. "Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria" (PDF). Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. FAO / WHO. Archived from the original (PDF) on October 22, 2012. Retrieved December 17, 2012.
  13. ^ Probiotics in food : health and nutritional properties and guidelines for evaluation. Food and Agriculture Organization of the United Nations, World Health Organization. Rome: Food and Agriculture Organization of the United Nations. 2006. ISBN 92-5-105513-0. OCLC 70928765. Archived from the original on July 1, 2023. Retrieved October 31, 2022.{{cite book}}: CS1 maint: others (link)[page needed]
  14. ^ "Guidelines for the Evaluation of Probiotics in Food" (PDF). Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food, London, Ontario, Canada. May 1, 2002. Archived from the original (PDF) on October 7, 2017.
  15. ^ a b Rijkers GT, Bengmark S, Enck P, et al. (2010). "Guidance for substantiating the evidence for beneficial effects of probiotics: current status and recommendations for future research". J. Nutr. 140 (3): 671S–676S. doi:10.3945/jn.109.113779. PMID 20130080.
  16. ^ Shane AL, Cabana MD, Vidry S, et al. (2010). "Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants". Gut Microbes. 1 (4): 243–253. doi:10.4161/gmic.1.4.12707. PMC 3023606. PMID 21327031.
  17. ^ Hill C, Guarner F, Reid G, et al. (August 2014). "Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic". Nature Reviews. Gastroenterology & Hepatology. 11 (8): 506–514. doi:10.1038/nrgastro.2014.66. hdl:2164/4189. PMID 24912386.
  18. ^ Mattila-Sandholm T, Myllärinen P, Crittenden R, et al. (2002). "Technological challenges for future probiotic foods". International Dairy Journal. 12 (2–3): 173–182. doi:10.1016/S0958-6946(01)00099-1. Archived from the original on June 16, 2022. Retrieved December 29, 2020.
  19. ^ a b Lactic Acid Fermentations. National Academies Press (US). 1992. Archived from the original on April 1, 2015. Retrieved March 30, 2021.
  20. ^ a b Breidt F, McFeeters RF, Perez-Diaz I, et al. (2013). "Fermented Vegetables" (PDF). Fermented Vegetables; In: Food Microbiology: Fundamentals and Frontiers, 4th Ed. Washington, DC: ASM Press. pp. 841–855. doi:10.1128/9781555818463.ch33. ISBN 978-1-55581-626-1. Archived (PDF) from the original on May 28, 2015. Retrieved May 19, 2016.
  21. ^ Oh CK, Oh MC, Kim SH (2004). "The Depletion of Sodium Nitrite by Lactic Acid Bacteria Isolated from Kimchi". Journal of Medicinal Food. 7 (1): 38–44. doi:10.1089/109662004322984680. PMID 15117551.
  22. ^ Pederson CS, Niketic G, Albury MN (1962). "Fermentation of the Yugoslavian pickled cabbage". Applied Microbiology. 10 (1): 86–89. doi:10.1128/AEM.10.1.86-89.1962. PMC 1057814. PMID 14484853.
  23. ^ Friedman Y, Hugenholtz J, De Vos WM, et al. (2006). "Safe use of genetically modified lactic acid bacteria in food. Bridging the gap between consumers, green groups, and industry". Electronic Journal of Biotechnology. 9 (4): E49–55. doi:10.2225/vol9-issue4-fulltext-12. Archived from the original on 14 August 2013. Retrieved 7 November 2007.
  24. ^ Moreno MR, Leisner JJ, Tee LK, et al. (2002). "Microbial analysis of Malaysian tempeh, and characterization of two bacteriocins produced by isolates of Enterococcus faecium". Journal of Applied Microbiology. 92 (1): 147–157. doi:10.1046/j.1365-2672.2002.01509.x. PMID 11849339. S2CID 20756449.
  25. ^ Ehrlich SD (May 24, 2011). "Lactobacillus acidophilus". University of Maryland Medical Center (UMMC). Archived from the original on September 11, 2015. Retrieved September 17, 2015.
  26. ^ Tanasupawat S, Thongsanit J, Okada S, et al. (2002). "Lactic acid bacteria isolated from soy sauce mash in Thailand". Journal of General and Applied Microbiology. 48 (4): 201–209. doi:10.2323/jgam.48.201. PMID 12469319.
  27. ^ Plessas S, Alexopoulos A, Voidarou C, et al. (2011). "Microbial ecology and quality assurance in food fermentation systems. The case of kefir grains application". Anaerobe. 17 (6): 483–485. doi:10.1016/j.anaerobe.2011.03.014. PMID 21497663.
  28. ^ Shiby VK, Mishra HN (2013). "Fermented milks and milk products as functional foods – a review". Critical Reviews in Food Science and Nutrition. 53 (5): 482–496. doi:10.1080/10408398.2010.547398. PMID 23391015. S2CID 3059150.
  29. ^ Mohammad SM, Mahmud-Ab-Rashid NK, Zawawi N (August 25, 2020). "Probiotic properties of bacteria isolated from bee bread of stingless bee Heterotrigona itama" (PDF). Journal of Apicultural Research. 60: 172–187. doi:10.1080/00218839.2020.1801152. ISSN 0021-8839. S2CID 225208290. Archived (PDF) from the original on March 27, 2023. Retrieved April 21, 2022.
  30. ^ Plengvidhya V, Breidt F Jr, Lu Z, et al. (2007). "DNA Fingerprinting of Lactic Acid Bacteria in Sauerkraut Fermentations". Applied and Environmental Microbiology. 73 (23): 7697–7702. Bibcode:2007ApEnM..73.7697P. doi:10.1128/AEM.01342-07. PMC 2168044. PMID 17921264.
  31. ^ Swain MR, Anandharaj M, Ray RC, et al. (2014). "Fermented Fruits and Vegetables of Asia: A Potential Source of Probiotics". Biotechnology Research International. 2014: 1–19. doi:10.1155/2014/250424. PMC 4058509. PMID 25343046.
  32. ^ "Table 1: Examples of traditional fermented fruits and vegetables, which are used in various parts of Asian subcontinent". Archived from the original on February 16, 2019. Retrieved February 16, 2019.
  33. ^ Guzel-Seydim ZB, Kok-Tas T, Greene AK, et al. (March 2011). "Review: functional properties of kefir". Crit Rev Food Sci Nutr. 51 (3): 261–268. doi:10.1080/10408390903579029. PMID 21390946. S2CID 19963871.
  34. ^ Farnworth ER (April 4, 2005). "Kefir-a complex probiotic" (PDF). Food Science and Technology Bulletin: Functional Foods. 2 (1): 1–17. CiteSeerX 10.1.1.583.6014. doi:10.1616/1476-2137.13938. Archived from the original (PDF) on May 14, 2014. Retrieved December 20, 2014.
  35. ^ Bauer B (July 8, 2017). "What is kombucha tea? Does it have any health benefits?". Mayo Clinic. Archived from the original on August 9, 2018. Retrieved September 5, 2018.
  36. ^ Wollan M (March 24, 2010). "Kombucha Tea Attracts a Following and Doubters". The New York Times. Archived from the original on July 12, 2018. Retrieved September 5, 2018.
  37. ^ Jarrell J, Cal T, Bennett JW (2000). "The Kombucha Consortia of yeasts and bacteria". Mycologist. 14 (4): 166–170. doi:10.1016/S0269-915X(00)80034-8.
  38. ^ Jonas R, Farah LF (1998). "Production and application of microbial cellulose". Polymer Degradation and Stability. 59 (1–3): 101–106. doi:10.1016/s0141-3910(97)00197-3.
  39. ^ Jayabalan R, Malbaša RV, Lončar ES, et al. (2014). "A Review on Kombucha Tea – Microbiology, Composition, Fermentation, Beneficial Effects, Toxicity, and Tea Fungus". Comprehensive Reviews in Food Science and Food Safety. 13 (4): 538–550. doi:10.1111/1541-4337.12073. PMID 33412713.
  40. ^ Boyle RJ, Robins-Browne RM, Tang ML (2006). "Probiotic use in clinical practice: what are the risks?". Am J Clin Nutr (Review). 83 (6): 1256–1264, quiz 1446–1447. doi:10.1093/ajcn/83.6.1256. PMID 16762934.
  41. ^ a b Aleman RS, Yadav A (December 26, 2023). "Systematic Review of Probiotics and Their Potential for Developing Functional Nondairy Foods". Applied Microbiology. 4 (1): 47–69. doi:10.3390/applmicrobiol4010004. ISSN 2673-8007.
  42. ^ Dore MP, Bibbò S, Fresi G, et al. (December 2, 2019). "Side Effects Associated with Probiotic Use in Adult Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". Nutrients. 11 (12): 2913. doi:10.3390/nu11122913. ISSN 2072-6643. PMC 6950558. PMID 31810233.
  43. ^ Lahtinen SJ, Davis E, Ouwehand AC (2012). "Lactobacillus species causing obesity in humans: where is the evidence?". Beneficial Microbes (Review). 3 (3): 171–174. doi:10.3920/BM2012.0041. PMID 22968407. Archived from the original on June 18, 2021. Retrieved July 1, 2020.
  44. ^ a b Feldman M (22 September 2016). "The New Market Profile of Probiotics Consumption". Natural Products Insider. Archived from the original on 5 September 2018. Retrieved 5 September 2018.
  45. ^ Meiling C (21 June 2018). "Yogurt ferments the dairy segment". The Daily Telegraph and China Daily. Archived from the original on 6 September 2018. Retrieved 5 September 2018.
  46. ^ 'Probiotic' As A General Descriptor (PDF) (Report). Yogurt & Live Fermented Milks Association (YLFA). Archived (PDF) from the original on 13 December 2014. Retrieved 12 December 2014.
  47. ^ "Probiotic health claims". Food Safety Authority of Ireland, Dublin. 2014. Archived from the original on 10 July 2017. Retrieved 13 December 2014.
  48. ^ "Regulation (EC) No 1924/2006 of the European Parliament and of the Council on 20 December 2006 on nutrition and health claims made on foods". European Commission, Brussels. 2006. Archived from the original on 2 February 2016. Retrieved 13 December 2014.
  49. ^ a b "Dannon Agrees to Drop Exaggerated Health Claims for Activia Yogurt and DanActive Dairy Drink FTC Charges that Evidence Supporting Benefits of Probiotics Falls Short". Federal Trade Commission, US Government. 15 December 2010. Archived from the original on 14 May 2017. Retrieved 9 May 2017.
  50. ^ a b Schmidt N (30 July 2014). "Warning letter to Plexus Worldwide Inc". Compliance Branch, Inspections, Compliance, Enforcement, and Criminal Investigations, US Food and Drug Administration. Archived from the original on 8 May 2017. Retrieved 9 May 2017.
  51. ^ "Phạt 257 triệu đồng với 7 cơ sở vi phạm về an toàn thực phẩm". Giáo dục Việt Nam (in Vietnamese). July 28, 2018. Retrieved September 24, 2024.
  52. ^ "Thu hồi thuốc Men vi sinh sống Biolac". baochinhphu.vn (in Vietnamese). January 3, 2017. Retrieved September 24, 2024.
  53. ^ "Bioamicus complete". Bioamicus (in Vietnamese). Retrieved September 24, 2024.
  54. ^ "Siết chặt quản lý thực phẩm chức năng". Báo Nhân Dân điện tử (in Vietnamese). January 1, 2013. Retrieved September 24, 2024.
  55. ^ "Đình chỉ lưu hành men vi sinh sống Biolac do không đạt chất lượng". baotainguyenmoitruong.vn (in Vietnamese). January 5, 2017. Retrieved September 24, 2024.
  56. ^ "Live & Active Culture Yogurt". National Yogurt Association. Archived from the original on 8 December 2014. Retrieved 12 December 2014.
  57. ^ Guidelines for the Evaluation of Probiotics in Food, Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food (PDF) (Report). London, Ontario, Canada: Food and Agriculture Organization and World Health Organization. April 2002. Archived (PDF) from the original on 1 August 2014. Retrieved 12 December 2014.
  58. ^ Sanders ME (2000). "Considerations for Use of Probiotic Bacteria to Modulate Human Health". The Journal of Nutrition. 130 (2S Suppl): 384S–390S. doi:10.1093/jn/130.2.384S. PMID 10721912.
  59. ^ Ferdousi R, Rouhi M, Mohammadi R, et al. (Winter 2013). "Evaluation of probiotic survivability in yogurt exposed to cold chain interruption". Iranian Journal of Pharmaceutical Research. 12 (Suppl): 139–144. ISSN 1735-0328. PMC 3813376. PMID 24250681.
  60. ^ Gismondo MR, Drago L, Lombardi A (1999). "Review of probiotics available to modify gastrointestinal flora". Int. J. Antimicrob. Agents. 12 (4): 287–292. doi:10.1016/s0924-8579(99)00050-3. PMID 10493604.
  61. ^ Tortora GJ, Funke BR, Case CL (2010). "5". Microbiology An Introduction (10th ed.). San Francisco, CA: Pearson Benjamin Cummings. p. 135. ISBN 978-0-321-58202-7.
  62. ^ Metchnikoff E (2004). The prolongation of life : optimistic studies. P. Chalmers, Sir Mitchell. New York: Springer Pub. ISBN 978-0-8261-1877-6. OCLC 287028845. Archived from the original on July 1, 2023. Retrieved October 31, 2022.[page needed]
  63. ^ "Arteriosclerosis and intestinal poisons". [a contemporary review of Metchnikoff's work] JAMA 1910, 55:2311–2312.
  64. ^ Vaughan RB (July 1965). "The romantic rationalist: A study of Elie Metchnikoff". Medical History. 9 (3): 201–215. doi:10.1017/S0025727300030702. PMC 1033501. PMID 14321564.
  65. ^ Tissier, H. 1900. Recherchers sur la flora intestinale normale et pathologique du nourisson. Thesis, University of Paris, Paris, France.
  66. ^ Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, et al. (2012). "Probiotic Mechanisms of Action". Annals of Nutrition and Metabolism. 61 (2): 160–174. doi:10.1159/000342079. PMID 23037511. S2CID 1295886. Archived from the original on May 25, 2021. Retrieved December 29, 2020.
  67. ^ Nißle A (1918). "Die antagonistische Behandlung chronischer Darmstörungen mit Colibakterien". Medizinische Klinik. 1918 (2): 29–33.
  68. ^ Altenhoefer A, Oswald S, Sonnenborn U, et al. (April 2004). "The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens". FEMS Immunology & Medical Microbiology. 40 (3): 223–229. doi:10.1016/S0928-8244(03)00368-7. PMID 15039098.
  69. ^ a b Cheplin HA, Rettger LF (December 1920). "Studies on the Transformation of the Intestinal Flora, with Special Reference to the Implantation of Bacillus Acidophilus: II. Feeding Experiments on Man". Proceedings of the National Academy of Sciences of the United States of America. 6 (12): 704–705. Bibcode:1920PNAS....6..704C. doi:10.1073/pnas.6.12.704. PMC 1084701. PMID 16576567.
  70. ^ Rettger FL (1935). Lactobacillus acidophilus & its therapeutic application. Yale Univ. Pr. OCLC 250265817. Archived from the original on July 1, 2023. Retrieved October 31, 2022.
  71. ^ a b c d Fuller R (May 1989). "Probiotics in man and animals". The Journal of Applied Bacteriology. 66 (5): 365–378. doi:10.1111/j.1365-2672.1989.tb05105.x. PMID 2666378.
  72. ^ Lilly DM, Stillwell RH (1965). "Probiotics: Growth-promoting factors produced by microorganisms". Science. 147 (3659): 747–748. Bibcode:1965Sci...147..747L. doi:10.1126/science.147.3659.747. PMID 14242024. S2CID 26826201.
  73. ^ Sperti GS (1971). Probiotics. West Point, CT: AVI Publishing Co. ISBN 978-0-87055-099-7.[page needed]
  74. ^ Parker RB (1974). "Probiotics, the other half of the antibiotic story". Animal Nutrition and Health. 29: 4–8.
  75. ^ Tannock GW (September 2003). "Probiotics: time for a dose of realism". Current Issues in Intestinal Microbiology. 4 (2): 33–42. PMID 14503687.
  76. ^ Fuller R (2012). Probiotics: the scientific basis. Springer Netherlands. ISBN 978-94-011-2364-8. OCLC 958540533. Archived from the original on July 1, 2023. Retrieved October 31, 2022.[page needed]
  77. ^ Alvarez-Olmos MI, Oberhelman RA (2001). "Probiotic agents and infectious diseases: a modern perspective on a traditional therapy". Clin. Infect. Dis. 32 (11): 1567–1576. doi:10.1086/320518. PMID 11340528.
  78. ^ Liddell HG, Scott R (eds.). "βιωτικός". A Greek-English Lexicon. Archived from the original on April 25, 2023. Retrieved February 21, 2021 – via Perseus Project.
  79. ^ Hamilton-Miller JM, Gibson GR, Bruck W (October 2003). "Some insights into the derivation and early uses of the word 'probiotic'". Br. J. Nutr. 90 (4): 845. doi:10.1079/BJN2003954. PMID 14552330.
  80. ^ Hutkins RW, Krumbeck JA, Bindels LB, et al. (2016). "Prebiotics: why definitions matter". Curr Opin Biotechnol. 37: 1–7. doi:10.1016/j.copbio.2015.09.001. PMC 4744122. PMID 26431716.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  81. ^ Salminen S, van Loveren H (2012). "Probiotics and prebiotics: health claim substantiation". Microb Ecol Health Dis. 23. doi:10.3402/mehd.v23i0.18568. PMC 3747744. PMID 23990821.
  82. ^ "Scientific Opinion on the substantiation of a health claim related to a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophillus LA 104 and reducing intestinal discomfort pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (example, search EFSA for other opinion reports on probiotics". EFSA Journal. 11 (2): 3085. 2013. doi:10.2903/j.efsa.2013.3085.
  83. ^ "Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria" (PDF). Food and Agriculture Organization of the United Nations. October 2001. Archived from the original (PDF) on May 14, 2012. Retrieved May 14, 2012.
  84. ^ Rowland I, Capurso L, Collins K, et al. (2010). "Current level of consensus on probiotic science: Report of an expert meeting – London, 23 November 2009". Gut Microbes. 1 (6): 436–439. doi:10.4161/gmic.1.6.13610. PMC 3056112. PMID 21637035.
  85. ^ Wu GD, Chen J, Hoffmann C, et al. (2011). "Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes". Science. 334 (6052): 1051–1108. Bibcode:2011Sci...334..105W. doi:10.1126/science.1208344. PMC 3368382. PMID 21885731.
  86. ^ Million M, Raoult D (February 2013). "Species and strain specificity of Lactobacillus probiotics effect on weight regulation". Microbial Pathogenesis. 55: 52–54. doi:10.1016/j.micpath.2012.09.013. PMID 23332210.
  87. ^ Million M, Angelakis E, Paul M, et al. (August 2012). "Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals". Microbial Pathogenesis. 53 (2): 100–108. doi:10.1016/j.micpath.2012.05.007. PMID 22634320.
  88. ^ Lahtinen SJ, Davis E, Ouwehand AC (September 2012). "Lactobacillus species causing obesity in humans: where is the evidence?". Beneficial Microbes. 3 (3): 171–174. doi:10.3920/BM2012.0041. PMID 22968407. Archived from the original on June 18, 2021. Retrieved July 1, 2020.
  89. ^ a b Scott AM, Clark J, Julien B, et al. (June 18, 2019). "Probiotics for preventing acute otitis media in children". Cochrane Database of Systematic Reviews. 2019 (6): CD012941. doi:10.1002/14651858.CD012941.pub2. PMC 6580359. PMID 31210358.
  90. ^ Qamer S, Deshmukh M, Patole S (August 2019). "Probiotics for cow's milk protein allergy: a systematic review of randomized controlled trials". Eur. J. Pediatr. (Review). 178 (8): 1139–1149. doi:10.1007/s00431-019-03397-6. PMID 31230196. S2CID 195259677.
  91. ^ Cuello-Garcia CA, Brożek JL, Fiocchi A, et al. (2015). "Probiotics for the prevention of allergy: A systematic review and meta-analysis of randomized controlled trials". Journal of Allergy and Clinical Immunology. 136 (4): 952–961. doi:10.1016/j.jaci.2015.04.031. ISSN 0091-6749. PMID 26044853. Archived from the original on March 16, 2022. Retrieved December 12, 2019.
  92. ^ Lin J, Zhang Y, He C, et al. (September 2018). "Probiotics supplementation in children with asthma: A systematic review and meta-analysis". J Paediatr Child Health (Systematic review). 54 (9): 953–961. doi:10.1111/jpc.14126. PMID 30051941. S2CID 51723667.
  93. ^ a b c d Guo Q, Goldenberg JZ, Humphrey C, et al. (April 30, 2019). "Probiotics for the prevention of pediatric antibiotic-associated diarrhea". The Cochrane Database of Systematic Reviews. 4 (4): CD004827. doi:10.1002/14651858.CD004827.pub5. ISSN 1469-493X. PMC 6490796. PMID 31039287.
  94. ^ Su GL, Ko CW, Bercik P, et al. (June 2020). "AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders". Gastroenterology (Clinical guideline). 159 (2): 697–705. doi:10.1053/j.gastro.2020.05.059. PMID 32531291.
  95. ^ McFarlandfirst=LV (2006). "Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease". Am. J. Gastroenterol. 101 (4): 812–822. doi:10.1111/j.1572-0241.2006.00465.x. PMID 16635227. S2CID 7557917. Archived from the original on July 28, 2020. Retrieved June 30, 2019.
  96. ^ Szajewska H, Ruszczyński M, Radzikowski A (September 2006). "Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials". J Pediatr. 149 (3): 367–372. doi:10.1016/j.jpeds.2006.04.053. PMID 16939749. S2CID 28439228.
  97. ^ Sazawal S, Hiremath G, Dhingra U, et al. (June 2006). "Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials". Lancet Infect Dis. 6 (6): 374–382. doi:10.1016/S1473-3099(06)70495-9. PMID 16728323.
  98. ^ Arvola T, Laiho K, Torkkeli S, et al. (1999). "Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: A randomized study". Pediatrics. 104 (5): e64. doi:10.1542/peds.104.5.e64. PMID 10545590.
  99. ^ Doron SI, Hibberd PL, Gorbach SL (July 2008). "Probiotics for prevention of antibiotic-associated diarrhea". J Clin Gastroenterol. 42 (Suppl 2): S58–63. doi:10.1097/MCG.0b013e3181618ab7. PMID 18542041. S2CID 2070623.
  100. ^ Surawicz CM (July 2008). "Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea". J Clin Gastroenterol. 42 (Suppl 2): S64–70. doi:10.1097/MCG.0b013e3181646d09. PMID 18545161. S2CID 37993276.
  101. ^ Falagas M, Betsi G, Athanasiou S (July 1, 2007). "Probiotics for the treatment of women with bacterial vaginosis". Clinical Microbiology and Infection. 13 (7): 657–664. doi:10.1111/j.1469-0691.2007.01688.x. ISSN 1198-743X. PMID 17633390.
  102. ^ Petrova MI, Lievens E, Malik S, et al. (2015). "Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health". Frontiers in Physiology. 6: 81. doi:10.3389/fphys.2015.00081. ISSN 1664-042X. PMC 4373506. PMID 25859220.
  103. ^ Borges S, Silva J, Teixeira P (March 2014). "The role of lactobacilli and probiotics in maintaining vaginal health". Arch. Gynecol. Obstet. (Review). 289 (3): 479–489. doi:10.1007/s00404-013-3064-9. PMID 24170161. S2CID 23954527.
  104. ^ Robles-Vera I, Toral M, Romero M, et al. (April 2017). "Antihypertensive Effects of Probiotics". Curr. Hypertens. Rep. (Review). 19 (4): 26. doi:10.1007/s11906-017-0723-4. PMID 28315049. S2CID 3834130.
  105. ^ Agerholm-Larsen L, Bell ML, Grunwald GK, et al. (2002). "The effect of a probiotic milk product on plasma cholesterol: a meta-analysis of short term intervention studies". European Journal of Clinical Nutrition. 54 (11): 856–860. doi:10.1038/sj.ejcn.1601104. PMID 11114681.
  106. ^ Liu RT, Walsh RF, Sheehan AE (July 1, 2019). "Prebiotics and probiotics for depression and anxiety: A systematic review and meta-analysis of controlled clinical trials". Neuroscience and Biobehavioral Reviews. 102: 13–23. doi:10.1016/j.neubiorev.2019.03.023. ISSN 1873-7528. PMC 6584030. PMID 31004628.
  107. ^ Ansari F, Pourjafar H, Tabrizi A, et al. (2020). "The effects of probiotics and prebiotics on mental disorders: A review on depression, anxiety, Alzheimer, and autism spectrum disorders". Current Pharmaceutical Biotechnology. 21 (7): 555–565. doi:10.2174/1389201021666200107113812. ISSN 1873-4316. PMID 31914909. S2CID 210121155.
  108. ^ King CK, Glass R, Bresee JS, et al. (November 2003). "Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy". MMWR Recomm Rep. 52 (RR–16): 1–16. PMID 14627948. Archived from the original on October 28, 2014. Retrieved September 8, 2017.
  109. ^ Collinson S, Deans A, Padua-Zamora A, et al. (December 18, 2020). "Probiotics for treating acute infectious diarrhea". Cochrane Database Syst Rev. 2020 (12): CD003048. doi:10.1002/14651858.CD003048.pub4. PMC 8166250. PMID 33295643.
  110. ^ Cuello-Garcia CA, Brożek JL, Fiocchi A, et al. (2015). "Probiotics for the prevention of allergy: A systematic review and meta-analysis of randomized controlled trials". J. Allergy Clin. Immunol. (Systematic review & meta-analysis). 136 (4): 952–961. doi:10.1016/j.jaci.2015.04.031. PMID 26044853.
  111. ^ Szeto MD, Hassan S, Hamp A, et al. (November 1, 2021). "From the Cochrane Library: Probiotics for treating eczema". Journal of the American Academy of Dermatology. 86 (3): e127–e132. doi:10.1016/j.jaad.2021.10.032. PMID 34748863. S2CID 243825695.
  112. ^ Fenner J, Silverberg NB (2018). "Oral supplements in atopic dermatitis". Clin. Dermatol. (Review). 36 (5): 653–658. doi:10.1016/j.clindermatol.2018.05.010. PMID 30217278. S2CID 52278259.
  113. ^ Xu D, Fu L, Pan D, et al. (2022). "Role of probiotics/synbiotic supplementation in glycemic control: A critical umbrella review of meta-analyses of randomized controlled trials". Critical Reviews in Food Science and Nutrition. 64 (6): 1–19. doi:10.1080/10408398.2022.2117783. PMID 36052685. S2CID 252009294.
  114. ^ Hamilton-Miller JM (October 2003). "The role of probiotics in the treatment and prevention of Helicobacter pylori infection". International Journal of Antimicrobial Agents. 22 (4): 360–366. doi:10.1016/S0924-8579(03)00153-5. PMID 14522098.
  115. ^ "H Pylori Facts" (PDF). CDC.gov. Archived (PDF) from the original on January 12, 2019.
  116. ^ a b Reid G, Jass J, Sebulsky MT, et al. (October 2003). "Potential uses of probiotics in clinical practice". Clin. Microbiol. Rev. 16 (4): 658–672. doi:10.1128/CMR.16.4.658-672.2003. PMC 207122. PMID 14557292.
  117. ^ a b Ouwehand AC, Salminen S, Isolauri E (August 2002). "Probiotics: an overview of beneficial effects". Antonie van Leeuwenhoek. 82 (1–4): 279–289. doi:10.1023/A:1020620607611. PMID 12369194. S2CID 1870018. Archived from the original on December 2, 2022. Retrieved December 1, 2022.
  118. ^ Zhao Y, Dong BR, Hao Q (August 24, 2022). "Probiotics for preventing acute upper respiratory tract infections". The Cochrane Database of Systematic Reviews. 2022 (8): CD006895. doi:10.1002/14651858.CD006895.pub4. ISSN 1469-493X. PMC 9400717. PMID 36001877.
  119. ^ Wachholz PA, Nunes V, Polachini do Valle A, et al. (February 3, 2018). "Effectiveness of probiotics on the occurrence of infections in older people: systematic review and meta-analysis". Age and Ageing. 47 (4): 527–536. doi:10.1093/ageing/afy006. hdl:11449/164454. PMID 29415116.
  120. ^ Limketkai BN, Akobeng AK, Gordon M, et al. (July 17, 2020). Cochrane Gut Group (ed.). "Probiotics for induction of remission in Crohn's disease". Cochrane Database of Systematic Reviews. 2020 (7): CD006634. doi:10.1002/14651858.CD006634.pub3. PMC 7389339. PMID 32678465.
  121. ^ a b c Kaur L, Gordon M, Baines PA, et al. (March 4, 2020). Cochrane IBD Group (ed.). "Probiotics for induction of remission in ulcerative colitis". Cochrane Database of Systematic Reviews. 3 (3): CD005573. doi:10.1002/14651858.CD005573.pub3. PMC 7059959. PMID 32128795.
  122. ^ Iheozor-Ejiofor Z, Kaur L, Gordon M, et al. (March 4, 2020). Cochrane IBD Group (ed.). "Probiotics for maintenance of remission in ulcerative colitis". Cochrane Database of Systematic Reviews. 3 (3): CD007443. doi:10.1002/14651858.CD007443.pub3. PMC 7059960. PMID 32128794.
  123. ^ Saez-Lara MJ, Carolina Gomez-Llorente, Julio Plaza-Diaz, et al. (2015). "The Role of Probiotic Lactic Acid Bacteria and Bifidobacteria in the Prevention and Treatment of Inflammatory Bowel Disease and Other Related Diseases: A Systematic Review of Randomized Human Clinical Trials". Biomed Res Int (Systematic review). 2015: 1–15. doi:10.1155/2015/505878. PMC 4352483. PMID 25793197.
  124. ^ Moayyedi P, Ford AC, Talley NJ, et al. (March 2010). "The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review". Gut (Systematic review). 59 (3): 3253–3232. doi:10.1136/gut.2008.167270. PMID 19091823. S2CID 18281136.
  125. ^ Sharif S, Meader N, Oddie SJ, et al. (October 15, 2020). "Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants". The Cochrane Database of Systematic Reviews. 2020 (10): CD005496. doi:10.1002/14651858.CD005496.pub5. ISSN 1469-493X. PMC 8094746. PMID 33058137.
  126. ^ Davidson SJ, Barrett HL, Price SA, et al. (2021). "Probiotics for preventing gestational diabetes". Cochrane Database of Systematic Reviews. 2021 (4): CD009951. doi:10.1002/14651858.CD009951.pub3. ISSN 1465-1858. PMC 8094741. PMID 33870484.
  127. ^ Newlove-Delgado TV, Martin AE, Abbott RA, et al. (2017). "Dietary interventions for recurrent abdominal pain in childhood". Cochrane Database Syst Rev. 2017 (3): CD010972. doi:10.1002/14651858.CD010972.pub2. PMC 6464236. PMID 28334433. Overall, there is some evidence to suggest that probiotics may be effective in the treatment of RAP, in terms of improving pain in the shorter term. Clinicians may therefore consider probiotic interventions as part of the management strategy for children with RAP (Recurrent Abdominal Pain). However, we were unable to recommend the optimum strain and dosage of probiotics based on this review. The evidence for the effectiveness of probiotics was based largely on shorter-term outcomes. Further trials are required to assess whether improvements in pain are maintained over the longer term; these trials should also consider the importance of using validated and consistent scales to measure pain and other outcomes.
  128. ^ Heydari M, Kalani M, Ghasemi Y, et al. (2023). "The Effect of Ophthalmic and Systemic Formulations of Latilactobacillus sakei on Clinical and Immunological Outcomes of Patients With Dry Eye Disease: A Factorial, Randomized, Placebo-controlled, and Triple-masking Clinical Trial". Probiotics Antimicrob Proteins. doi:10.1007/s12602-023-10079-1. PMID 37256485. S2CID 258989191. Archived from the original on November 5, 2023. Retrieved October 6, 2023.
  129. ^ Shortliffe L (2011). "Chapter 116: Infection and Inflammation of the Pediatric Genitourinary Tract". In Wein AJ (ed.). Campbell-Walsh Urology. Vol. 4 (10th ed.). Saunders Elsevier. p. 3121. ISBN 978-1-4160-6911-9.
  130. ^ Khalesi S (2019). "A review of probiotic supplementation in healthy adults: helpful or hype?". European Journal of Clinical Nutrition. 73 (73): 24–37. doi:10.1038/s41430-018-0135-9. hdl:10072/381737. PMID 29581563. S2CID 4362284.
  131. ^ Islam MA, Yun CH, Choi YJ, et al. (2010). "Microencapsulation of live probiotic bacteria" (PDF). Journal of Microbiology and Biotechnology. 20 (1367–1377): 1367–1377. doi:10.4014/jmb.1003.03020. PMID 21030820. Archived (PDF) from the original on May 6, 2011. Retrieved January 28, 2011.
  132. ^ Timmerman HM, Koning CJ, Mulder L, et al. (November 2004). "Monostrain, multistrain and multispecies probiotics – A comparison of functionality and efficacy". Int. J. Food Microbiol. 96 (3): 219–233. doi:10.1016/j.ijfoodmicro.2004.05.012. PMID 15454313.
  133. ^ Williams EA, Stimpson J, Wang D, et al. (September 2008). "Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study". Aliment. Pharmacol. Ther. 29 (1): 97–103. doi:10.1111/j.1365-2036.2008.03848.x. PMID 18785988. S2CID 12217513.
  134. ^ Bee P (10 November 2008). "Probiotics, not so friendly after all?". The Times. London. Archived from the original on 11 May 2015. Retrieved 18 June 2010.
  135. ^ Dhewa T, Pant S, Mishra V (January 2014). "Development of freeze dried synbiotic formulation using a probiotic strain of Lactobacillus plantarum". Journal of Food Science and Technology. 51 (1): 83–89. doi:10.1007/s13197-011-0457-2. ISSN 0022-1155. PMC 3857416. PMID 24426051.
  136. ^ a b Fuller R (1991). "Probiotics in human medicine". Gut. 32 (4): 439–442. doi:10.1136/gut.32.4.439. PMC 1379087. PMID 1902810.
  137. ^ Fuller R. Probiotics, the Scientific Thesis. London: Chapman & Hall, 1992 [ISBN missing][page needed]
  138. ^ Reid G, Gaudier E, Guarner F, et al. (2010). "Responders and non-responders to probiotic interventions: how can we improve the odds?". Gut Microbes. 1 (3): 200–204. doi:10.4161/gmic.1.3.12013. PMC 3023600. PMID 21637034.
  139. ^ O'Hara AM, O'Regan P, Fanning A, et al. (2006). "Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius". Immunology. 118 (2): 202–215. doi:10.1111/j.1365-2567.2006.02358.x. PMC 1782284. PMID 16771855.
  140. ^ Huys G, Botteldoorn N, Delvigne F, et al. (2013). "Microbial characterization of probiotics – Advisory report of the Working Group "8651 Probiotics" of the Belgian Superior Health Council (SHC)". Molecular Nutrition & Food Research. 57 (8): 1479–1504. doi:10.1002/mnfr.201300065. PMC 3910143. PMID 23801655.
  141. ^ "Commentary by the Scientific Committee on Animal Nutrition on Data Relating to Toxin Production" (PDF). Scientific Opinion. European Commission, Health & Consumer Protection Directorate-General. December 2001. Archived (PDF) from the original on 29 June 2016. Retrieved 5 June 2016.
  142. ^ "Introduction of a Qualified Presumption of Safety (QPS) approach for assessment of selected microorganisms referred to EFSA". EFSA Journal. 587 (12): 1–16. 2007. doi:10.2903/j.efsa.2007.587.

Further reading

[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Probiotic&oldid=1252009712"